

Application for the following position in the EHRA Board:

President-Elect



1. Your Identity

Title: Professor, MD, PhD, FESC, FEHRA

Family Name(s): Leclercq

First Name(s): Christophe

Birth Date: 16/03/1961

Type of address: ☒ **Business** ☐ **Home**

Institute/Organisation: Centre Cradio-Pneumologique, CHU Pontchaillou

Department: Service de Cardiologie et Maladies Vasculaires

Address: 2 Rue Henri le Guilloux

Post Code/Zip: 35000

City: Rennes, France



2. General Curriculum Vitae (300 words max)

I graduated at Tours University Medical School in 1985. After my fellowship in the Department of Cardiology of Rennes University Hospital I was nominated Assistant Professor in 1992 then Associate Professor in 1999. During this time I performed my training in electrophysiology. After my PhD in 2000, I spent one year as a research fellow in the Johns Hopkins Hospital in Baltimore (USA). Since 2001, I am Professor of Cardiology in Rennes University and head of the department of cardiology since 2015 (86 beds and cardiac emergency room).

I have an important clinical activity with the responsibility of a 22 beds unit mainly dedicated to cardiac arrhythmias. I am also in charge of the pacemakers and ICDs program in our department (more than 650 implantations / year).

I am also responsible for the clinical research unit with 7 research nurses involved in the development and approval of new implantable device therapy.

I am especially involved in heart failure device therapy I was PI and member of the steering committees of several trials (PROSPECT, B-LEFT, CHAMP, SEPTAL-CRT, ADAPTIVE-CRT, MORE CRT-MPP, SMART-CRT ...)

I have published over 210 manuscripts (H index : 47) and I am a yearly lecturer at the HRS, EUROPACE and ESC meetings and regularly invited at the AHA meeting.

I am a reviewer for the major cardiology journals and member of the board of the European Heart Journal, EUROPACE and Circulation.

I am member of the executive board of the French Society of Cardiology since 2009

I head the nominating committee of the physicians in Rennes Hospital and hold the vice-president position on the medical board in Rennes University Hospital

I also take on administrative responsibilities in the ESC and EHRA (see below)

During my leisure time I enjoy sports (running and swimming), travelling with my family to discover new landscapes and cultures...





3. Previous experience(s) within EHRA, ESC or your National Cardiac Society?

ESC experiences

- Member of the ESC nominating committee in 2011
- Member of the Congress program Committee of the annual ESC meeting 2010-2016
- Chair of the Arrhythmias Congress Program Committee of the annual ESC meeting 2012-2016
- Active speaker for GSA since 2013
- Member of the task force of the 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy
- Member of the ESC Board since 2016
- Member of the ESC guidelines and GSA committees since 2016

EHRA experiences

- Member of the EHRA education committee from 2009 to 2013
- co-director of the EHRA Cardiac Pacing Course from 2011 to 2013 and lecturer in this course since 2009
- Member of the EHRA board from 2013
- Member of the EHRA executive board since 2013
- Secretary on the EHRA Board from 2013 to 2015
- International coordinator and member of the EHRA board 2015-2017
- Program chair of the EHRA 2018 congress

French Society of Cardiology experiences

- Member of the French Society of Cardiology Board since 2009
- Member of the French Society of Cardiology Executive Board 2009-2015 and since 2018





4. Why are you interested in joining EHRA Board (150 words max)?

To increase my investment in the EHRA board since my involvement in 2013,. This 5 years on the EHRA Board have already given me a good knowledge of EHRA's strengths but also the opportunities for the association.

To reinforce EHRA's role in the worldwide EP community by developing collaboration with intercontinental EP societies

To reinforce EHRA's identity inside and outside ESC.

To better attract the young EP generation, our future, showing them that EHRA is their association!

To create with the EP national WGs a unique network for sharing practices and scientific works, creating a more concrete and visible link between us.

Education is a major success for EHRA. Despite the complexity of MedTech regulation with product-training education from industry, 2018 EHRA congress demonstrated that EHRA is a mandatory partner for independent education. A round table needs to be organized to define the expectations and role of each.

Last but not least... to better involve our patients.





5. How will you coordinate your EHRA appointment with your daily clinical/research workload?

I am involved in clinical cardiology, EP procedures and research on cardiac devices in heart failure. During the past years, as chair of the department of cardiology in my Hospital, I with Pr Mabo organized the promotion of 2 young electrophysiologists (Dr Béhar and Martins) to reinforce our EP team. Our team now includes 5 Eps. This allows me to have more time for “administrative” functions. I plan to up to 1 to 1.5 days a week dedicated to the function of president elect but I wish (or will keep) to keep clinical, research and EP activities. All my team supports me in this candidacy and is ready to work harder to compensate the time and energy I will spend for EHRA.

Of Course I will have to withdraw from some other administrative tasks, especially at the level of my institution.

Finally, I am a hard worker and a light sleeper.....

On my computer screen saver it is written.... just do it!!!





6. Please list your conflict of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
- Payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
- Receipts of royalties for intellectual property
- Research funding (departmental or institutional)

- ☐ **Company Biotronik**
- ☐ **Product or therapeutic area:**
<10 K€/year x 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- ☐ **Company (Abbott):**
- ☐ **Product or therapeutic area:**
<10 K€/ year x 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- ☐ **Company (Medtronic):**
- ☐ **Product or therapeutic area:**
x<10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- ☐ **Company (Livanova):**
- ☐ **Product or therapeutic area:**
x<10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- ☐ **Company (Boston):**
- ☐ **Product or therapeutic area:**
x<10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- ☐ **Company (Bayer):**
- ☐ **Product or therapeutic area:**
x<10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- ☐ **Company (BMS):**
- ☐ **Product or therapeutic area:**
x<10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year

☐ **Position of influence declaration:**

- Nothing to declare

